Trials & R&D · first seen 5h ago, updated 5h ago
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact
Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs. The post Lilly A…
Summary from MedCity News.